RECOVERY / RESEARCH PHASE
DSIP (Delta Sleep-Inducing Peptide)
Subcutaneous injection, Intravenous, Intranasal
Overview
A naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood of rabbits during induced sleep. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep through interactions with the GABAergic system and hypothalamic sleep centers.
Mechanism of Action
It also exhibits stress-protective, analgesic, and neuromodulatory properties.
​Research Summary & Key Findings
Clinical studies showed normalization of disturbed sleep patterns in insomnia patients without next-day sedation. Demonstrated reduction in stress-related corticotropin levels. Limited clinical data but preclinical models show consistent sleep-promoting and neuroprotective effects.
Clinical Status
RESEARCH PHASE
DSIP (Delta Sleep-Inducing Peptide) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
Subcutaneous injection (weekly)
Oral (daily - Rybelsus)
References
PRIMARY LITERATURE
PRIMARY LITERATUREPeer-reviewed literature indexed by the National Library of Medicine.
Registered interventional and observational studies, including status and phase.
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.